- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Fortis to sell Dubai pathology business
In order to focus on growth in the India market, under its diagnostics business chain SRL, Fortis Hospital’s international market strategy has taken a backseat with the hospital now reported to shut down its pathology business in Dubai.
Currently Fortis is evaluating various proposals for the sale of its pathology business in Dubai, as confirmed by vccircle.com.
The report in the vccircle also points out the fact that Fortis is now focused to expand its business in India, after having being designated as one of the few Indian companies with a strong international market focus earlier. The market strategy however, is now reversed with more and more funds being invested in the Indian diagnostics business.
Fortis is reported to have earlier sold off its stake in Singapore based healthcare services unit RadLink-Asia Pte Ltd and its subsidiaries to Fullerton Healthcare Group for S$111 million (approximately $83.5 million or Rs 530 crore).
Earlier in 2010, Fortis promoters had also locked themselves into a takeover battle with Khazanah for Singapore's Parkway. They had later pulled out from the battle and sold their own stake to Khazanah.
Currently Fortis is evaluating various proposals for the sale of its pathology business in Dubai, as confirmed by vccircle.com.
The report in the vccircle also points out the fact that Fortis is now focused to expand its business in India, after having being designated as one of the few Indian companies with a strong international market focus earlier. The market strategy however, is now reversed with more and more funds being invested in the Indian diagnostics business.
Fortis is reported to have earlier sold off its stake in Singapore based healthcare services unit RadLink-Asia Pte Ltd and its subsidiaries to Fullerton Healthcare Group for S$111 million (approximately $83.5 million or Rs 530 crore).
Earlier in 2010, Fortis promoters had also locked themselves into a takeover battle with Khazanah for Singapore's Parkway. They had later pulled out from the battle and sold their own stake to Khazanah.
Next Story